Jinwon Life Sciences Begins Phase 2 Clinical Trial of Oral COVID-19 Treatment in Domestic Patients

[Asia Economy Reporter Jang Hyowon] Genewell Life Sciences announced on the 23rd that it will begin clinical research on patients in South Korea, where the Omicron variant is dominant, as it has recruited about 90% of the clinical trial participants for the global Phase 2 clinical trial of GLS-1027, an oral therapeutic that prevents patients hospitalized with COVID-19 infection from worsening to severe conditions.

The company stated that the Phase 2 clinical study of GLS-1027 is being conducted in multiple countries including the United States and Europe. Currently, out of 132 participants, 116 have been enrolled, 87 participants have completed the clinical study, and 29 participants are undergoing the clinical study.

Park Young-geun, CEO of Genewell Life Sciences, said, “GLS-1027 suppresses the progression to severe pneumonia through anti-inflammatory responses rather than antiviral action, so it is effective regardless of the variant and is an appropriate treatment in situations where infections are surging. In particular, it does not affect cytochrome P450 3A4 isoenzyme related to drug metabolism in the liver, so it is expected to have excellent safety with no restrictions on combination with other drugs.”

He added, “Since the administration and clinical evaluation period of GLS-1027 is short, within two months, we will promptly complete the enrollment of the remaining 16 participants at domestic clinical institutions, secure interim clinical results within the first half of this year, and prepare to enter Phase 3 clinical trials.”

This content was produced with the assistance of AI translation services.